Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$661K Buy
551
+25
+5% +$25.5K 0.18% 39
2026
Q1
$484K Buy
526
+63
+14% +$63.9K 0.15% 40
2025
Q4
$498K Buy
463
+139
+43% +$133K 0.16% 42
2025
Q3
$247K Buy
324
+2
+0.6% +$1.49K 0.08% 59
2025
Q2
$251K Sell
322
-4
-1% -$3.11K 0.09% 56
2025
Q1
$269K Buy
326
+21
+7% +$17.5K 0.11% 49
2024
Q4
$235K Buy
305
+46
+18% +$38.1K 0.1% 50
2024
Q3
$229K Buy
259
+8
+3% +$7.19K 0.1% 51
2024
Q2
$227K Buy
+251
New +$201K 0.11% 46
2023
Q3
Sell
-8
Closed -$3.48K 308
2023
Q2
$3.48K Buy
8
+3
+60% +$1.26K ﹤0.01% 192
2023
Q1
$2.16K Buy
+5
New +$1.69K ﹤0.01% 206

Other funds holding LLY

25 LLC's LLY Position: Q2 2026 in Review

25 LLC increased its Eli Lilly (LLY) stake by 4.8% in Q2 2026, buying an estimated $25.5K and bringing the position to 551 shares worth $661K. The position accounts for 0.18% of the portfolio, ranked #39.

25 LLC first reported a position in LLY in Q1 2023 and has held it in 11 quarters since. 4,635 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • 25 LLC held 551 shares of Eli Lilly worth $661K as of Q2 2026.
  • 25 LLC bought 25 Eli Lilly shares in Q2 2026, an estimated $25.5K.
  • Eli Lilly made up 0.18% of 25 LLC's portfolio in Q2 2026, its #39 holding.
  • 25 LLC first reported a position in Eli Lilly in Q1 2023 and has held it in 11 quarters since.
  • 4,635 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on 25 LLC's 13F filing for Q2 2026, filed 28 Jul 2026.